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in the young age group. The ratio of dose reduction of the ﬁrst-cycle in 
initial chemotherapy were 14.8% in the young age group and 55.9% in 
the old age group(p<0.001). Despite lower dose-intensity of chemother-
apy, median overall survival of the old age group was similar to that of 
the young age group(12.6 vs. 13.9 months, p=0.3471). Among the old 
age group, the average of number of regimens(2.22 of elderly patients 
without comorbidity vs. 2.39 of those with comorbidity, respectively; 
p=0.454) and cycles(8.04 vs. 9.84, p=0.105) per head were similar 
between elderly patients without comorbidity and with comorbidity. 
There was no signiﬁcant difference in median overall survival between 
elderly patients without comorbidity and with comorbidity(11.2 vs 14.8 
months, p=0.3054). Elderly patients with dose-reduction of the ﬁrst-
cycle in the initial chemotherapy received signiﬁcantly less number of 
regimens(2.09 of elderly patients with dose-reduction vs. 2.62 of those 
without dose-reduction, p=0.017) and cycles of chemotherapy(7.79 vs. 
10.58, p=0.016) as compared with elderly patients without dose-reduc-
tion. Although elderly patients with dose-reduction received less num-
ber of regimens and cycles of chemotherapy, median overall survival 
of elderly patients with dose-reduction was equivalent to that of elderly 
patients without dose-reduction(11.2 vs. 14.8 months, p=0.0742).
Conclusions: Although signiﬁcantly lower dose-intensity of chemo-
therapies were conducted in elderly patients with advanced or recurrent 
NSCLC, the efﬁcacy and survival of elderly patients were similar to 
those of young patients. The optimal dose and schedule of palliative 
chemotherapy for elderly patients with advanced or recurrent NSCLC 
should be redeﬁned.
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Background: During anti-cancer chemotherapy for lung cancer and 
other various malignancies, some patients suffer due to sudden onset of 
dyspnea and acute respiratory failure with acute lung injury, diagnosed 
by chest CT and clinical ﬁndings. It is difﬁcult to make an immediate 
differential diagnosis of chemotherapy induced acute lung injury and 
other causes of acute lung injury, such as respiratory infection or sepsis.
Methods: We analyzed the clinical and laboratory characteristics, 
causative chemotherapeutic drugs, treatment responses of suspicious 
chemotherapeutic drug induced acute lung injury retrospectively.
Results: Fourteen patients with lung cancer and two cases of other 
cancer (esophageal and breast cancer) were included. The probable 
causative chemotherapeutic drugs were geﬁtinib (5 cases), docetaxel 
(5 cases), paclitaxel (1 case), navelbine (2 cases), gemcitabine (1 case), 
epirubicin (1 case), and etoposide (1 case). The most frequent radio-
lographic ﬁnding was ground glass attenuation detected in chest CT. 
Most of the patents were treated with broad spectrum antibiotics and 
steroid (methylprednisolone 125-250mg bid intravenously for 2-5 days 
or prednisolone 0.5-1mg/kg/day for 1-2 weeks) and mechanical ventila-
tion if needed. Twelve patients were survived, but 3 patients died due 
to reparatory failure and accompanied complications. The APACHE II 
score was high in non-survivors (23) compared to survivors (14.5). The 
patients with combined respiratory infection conﬁrmed by microbio-
logical studies showed unfavorable treatment response. The patients 
with more severe initial respiratory dysfunction requiring mechanical 
ventilatory supports showed poor prognosis.
Conclusion: It is important to make an early diagnosis and early 
initiation of treatment for acute lung injury associated with anti-cancer 
chemotherapy.
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Background: RRM1 is related to the resistance for gemcitabine che-
motherapy in patients who revealed high RRM1 expression in tumor 
tissues. This study was designed under the hypothesis that the poly-
morphism in RRM1 promoter, which regulate RRM1 gene expression, 
could impact on the result of the therapeutic response and the prognosis 
of the patients with lung cancer treated with gemcitabine.
Methods: A retrospective data set of 97 patients with advanced 
NSCLC treated with gemcitabine as the ﬁrst-line chemotherapy was 
studied. Allelotyping of RRM1 gene was performed with real-time 
PCR and sequencing using genomic DNA achieved from peripheral 
white blood cells.
Results: The frequencies of RRM1 gene promoter allelotypes were 
RR37CC-R524TT in 58, RR37AC-RR524CT in 29, and others in 
10. The response rate for gemcitabine containing chemotherapy was 
49.5%. When the author analyzed the therapeutic responses according 
to RRM1 promoter allelotypes, 65.5% in RR37AC-RR524CT group 
and 43.1% in RR37CC-RR524TT group (P = 0.049). There were no 
statistically signiﬁcant differences in overall survival and progression 
free survival by the two allelotypes. 
Conclusions: The response rate was higher in the patients’ group 
with RR37AC-RR524CT in which we expected to show lower level 
of RRM1 gene expression than in the patients’ group with RR37CC-
RR524TT, and that result was thought to correspond to our hypothesis. 
If further studies would verify and supplement the result of our study, 
we can expect to improve the prognosis of the advanced non-small cell 
lung cancer through the application of our result for the patient-tailored 
therapy.
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Background: Second-line chemotherapy offers advanced non-small 
cell lung cancer (NSCLC) patients a small but signiﬁcant survival 
improvement. Docetaxel is usually administered as a 3-week schedule. 
But it has a high toxicity burden. Therefore, weekly schedule has been 
explored in several trials. In this retrospective study, we compared the 
efﬁcacy and safety of weekly schedule and 3-week schedule docetaxel 
monotherapy as a second-line setting.
Methods: Docetaxel was administered with 75 mg/m2 on day 1 every 3 
week or 37.5 mg/m2 on day 1, 8 every 3 week until disease progression 
or severe toxicity developed.
Results: From October 2003 to March 2006, a total 38 patients 
received docetaxel monotherapy and 37 patients can be evaluated. A 
total 141 cycles were administered and evaluated. The median overall 
survival was 13.3 months (95% Conﬁdence interval; 6.3 ~ 20.3) in 
the weekly schedule and 10.7 months (95% Conﬁdence interval; 8.3 ~ 
13.0) in the 3-week schedule (p=0.41). The median time to progression 
was 3.0 months (95% Conﬁdence interval; 1.9 ~ 4.0) and 2.8 months 
(95% Conﬁdence interval; 1.0 ~ 4.6), respectively (p=0.41). Response 
rate was 16.7% in weekly schedule and 21.1% in the 3-week schedule. 
Major hematologic toxicity was grade 3-4 neutropenia (3-week: 39.2%, 
weekly: 11.9%). Non-hematologic toxicities were similar between the 
two schedules. There were no treatment-related deaths.
Conclusions: Docetaxel weekly schedule is very well tolerable and 
comparable activity with 3-week schedule. Considering efﬁcacy and 
tolerability, it can be alternative schedule of standard treatment as a 
second-line setting. 
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Background: We have previously shown the optimal dose of biweekly 
Gemcitabine and Paclitaxel (GEM/PAC) for the treatment of refractory 
and/or resistant patients with non-small cell lung cancer (NSCLC). 
We conducted a phase II study of this combination chemotherapy to 
evaluate the efﬁcacy and safety of biweekly GEM/PAC in patients with 
NSCLC as a second line chemotherapy after platinum-based chemo-
therapy.
Methods: Patients with measurable tumor who had received one previ-
ous chemotherapy or chemotherapy/radiation regimen were eligible. 
PAC (150mg/m2) was administered ﬁrst over one hour followed by 
GEM (1000mg/m2) over 30minutes and repeated biweekly at least 4 
cycles.
Results: Thirty-one patients were enrolled, median age of 64 yr (range 
39 to 75). Nine were female and twenty-two were male. Stage 3b was 
eleven and Stage 4 was twenty. Thirteen patients had a performance 
status 0, sixteen were 1, and two were 2. Twenty-six patients (84%) 
were received with platinum compound plus Docetaxel regimen. Bi-
weekly GEM/PAC was performed with the median cycles of 5.2 (1-20 
cycles). Partial response observed in seven cases (23%), and stable 
disease was seen in eighteen (58%). Median survival time after GEM/
PAC was seven months. Over grade 3 or 4 hematological toxicity (3%) 
and neurotoxicity (3%) were observed in one patient, respectively. One 
patient who received only one cycle of this chemotherapy developed 
pulmonary toxicities, resulted in fatal respiratory failure.
Conclusions: The biweekly GEM/PAC combination chemotherapy 
was active and well tolerated as a second-line therapy in patients with 
NSCLC. Paclitaxel might be a promising and alternative agent in pa-
tient with previously treated with Docetaxel as ﬁrst line.
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In our study, patients who were diagnosed as local advanced NSCLC 
and treated with gemsitabine plus cisplatine (GP) regimen, were evalu-
ated retrospectively. 77 patients ( 72 male and 5 women) who were 
taken more then two cycles of GP chemotherapy and reevaluated after 
chemotherapy is admitted to the study. Patients median age was 65. 
Patiens were evaluated with their stages, responce to the chemotheray 
after 2 and 4 th cycle with WHO responce criteria, time to progression, 
toxicity proﬁles and EQRLC quality of life assesment of 24 patents. 
Median chemotherapy cycle is 3 and 5% complete responce, 39% 
partial responce, 30% stable disease, 26% progressive disease were re-
staged after 2 course of chemotherapy. Median survival is 12,5 mounth 
and time to progression is 5 mounth. Neutropenia and anemia are the 
most common hematological toxicities whilst emezis and allopesia are 
the most common nonhematological toxicities .
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Introduction: Sixty percent of all neoplasms and two-thirds of all 
deaths due to cancer occur in persons older than 65 years. More than 
50% of patients with lung cancer are older than 65 years and 30% older 
than 70 years. With more persons surviving to older age treatment of 
the elderly with lung cancer has become an important issue.
Material and Method: All patients 75 years or older with lung cancer 
seen at the Department of Respiratory Medicine and Allergy, Karolin-
ska Hospital from 2003 to 2005 were retrospective reviewed. In all, 
334 patients were analyzed. 
Results: The mean age was 80.5 years, 94 (58.1%) were men. 94% of 
the males and 79% of the females were smokers or former smokers. 
246 (73.6%) had PS 0-2. 9.2% had SCLC, 19.9% adenocarcinoma, 
and 6.7% squamous cell carcinoma. 23.9% had clinical lung cancer 
and the others broncheoalveolar cell carcinoma or low differentiated 
